Page 7 - Private Equity Exits via Initial Public Offerings 2016

Date Company Sector Private Market IPO Sell down as a Price Aggregate Banks Under- Commission Total Private equity Private equity
equity cap size proportion of change sponsor written /fee estimated sponsor sponsor lock-up
sponsor(s) at IPO (£m) 1 IPO (%) 2 since retained structure expenses relationship + orderly market
(£m) IPO stake at (including agreement periods (months
3
4
(%) IPO (%) commissions (key terms) from IPO)
(£m)
18 Cerillion plc IT Livingbridge 22.4 10.0 No sell down 98.0 17.8 Shore No 5% 1.5 N/A N/A
Mar Capital commission
2016 Corporate
finance fee
of £200,000
29 MaxCyte, Pharma, Intersouth 30.4 7.8 No sell down 152.1 44.8 Panmure No 5% 2.2 N/A 12+12
Mar Inc. Biotech and Partners, Gordon commission
2016 Healthcare Bost-Jackson, Corporate
Harbert finance fee
Ventures, MASA of £250,000
Life Sciences,
Medinet
15 Osirium IT Harwell 16.2 7.8 32.0 - 15.7 19.1 Panmure No 4% 1.0 N/A 12+12
April Technologies Capital, Gordon commission
2016 plc Interogo Corporate
(Ikea finance fee
Foundation) of £250,000
5 Morses Club Financial Rcapital 139.7 67 Undisclosed 17.6 13.6 Numis, No Undisclosed 2.9 Right to 6+6
May plc Panmure appoint 1
2016 Gordon, director for so
Deloitte long as hold
Corporate 20% or more
Finance of voting rights
15 Oncimmune Pharma, Balderton 66.3 9.8 All of the shares - 0.4 51.0 Zeus No 5% 1.2 N/A 12+12
May Holdings plc Biotech and Capital offered in the commission
2016 Healthcare IPO were sold Corporate
by the private finance fee
equity of £250,000
sponsor(s)

www.dwf.law